Health and Healthcare

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Chris Lange | Oct 4, 2017 at 10:10 AM EDT

Why Catabasis Shares Are Surging

Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a…

Chris Lange | Oct 2, 2017 at 1:40 PM EDT

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade…

Jon C. Ogg | Oct 2, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one…

Chris Lange | Sep 30, 2017 at 8:20 AM EDT

Major Biotech, Pharma and FDA Catalysts Coming in October

24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.

Chris Lange | Sep 6, 2017 at 10:15 AM EDT

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its…

Lee Jackson | Apr 5, 2017 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Wednesday’s top analyst upgrades, downgrades and initiations included AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor and Wynn Resorts,

Lee Jackson | Jan 19, 2017 at 8:40 AM EST

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the…

Chris Lange | Jan 10, 2017 at 3:30 PM EST

Tuesday’s Top Biopharma Movers

Considering the new Trump administration, there is an increasingly positive sentiment in the health care sector. In the past year,…

Jon C. Ogg | Jan 3, 2017 at 9:05 AM EST

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone and Sarepta.

Trey Thoelcke | Dec 30, 2016 at 11:15 AM EST

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

Jon C. Ogg | Dec 14, 2016 at 8:35 AM EST

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm and Xilinx.

Chris Lange | Oct 4, 2016 at 10:35 AM EDT

Summit Therapeutics Skyrockets on Sarepta Deal

Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a…

Chris Lange | Oct 2, 2016 at 10:05 AM EDT

Top 6 Biopharma Gainers of the Past Week

Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood…

Chris Lange | Sep 29, 2016 at 12:40 PM EDT

Catabasis Skyrockets on Sarepta Partnership

Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint…

Chris Lange | Sep 22, 2016 at 9:35 AM EDT

How Sarepta Is Cashing In on Its FDA Homerun

Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally…

1 … 3 4 5 6 7 … 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Why Catabasis Shares Are Surging

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

Major Biotech, Pharma and FDA Catalysts Coming in October

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

Tuesday’s Top Biopharma Movers

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

Summit Therapeutics Skyrockets on Sarepta Deal

Top 6 Biopharma Gainers of the Past Week

Catabasis Skyrockets on Sarepta Partnership

How Sarepta Is Cashing In on Its FDA Homerun

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Why Catabasis Shares Are Surging

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

Major Biotech, Pharma and FDA Catalysts Coming in October

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

Tuesday’s Top Biopharma Movers

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

Summit Therapeutics Skyrockets on Sarepta Deal

Top 6 Biopharma Gainers of the Past Week

Catabasis Skyrockets on Sarepta Partnership

How Sarepta Is Cashing In on Its FDA Homerun

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s